Cybin Provides Corporate Update; Says Second Half Of 2023 Will Be Pivotal As It Expects Topline Clinical Data Readouts
Portfolio Pulse from Benzinga Newsdesk
Cybin expects topline clinical data readouts in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004. The company believes this will provide the necessary capital to complete clinical milestones and focus on clinical execution.
June 08, 2023 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin expects topline clinical data readouts in late Q3 2023, which may provide the necessary capital to complete clinical milestones and focus on clinical execution.
The expected topline clinical data readouts in late Q3 2023 for CYB003 and CYB004 will likely have a positive impact on Cybin's stock price. The successful completion of these clinical milestones may attract more investors and increase the company's valuation, leading to a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100